Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 2302981

Complement levels in patients with hepatic dysfunction.

R T Ellison·C R Horsburgh·J Curd
View original source ↗Export metadata ↓

Abstract

Total hemolytic complement activity and serum complement protein concentrations were compared in 17 hospitalized patients with normal hepatic function and 16 patients with liver disease due to alcohol (15 patients) or acetaminophen toxicity (one patient). In contrast to the control patients, individuals with hepatic dysfunction had decreased total CH50 levels and low concentrations of total C3, C4, C5, factor B, and the regulatory proteins factor I and beta-1H. These patients also had increased C4d/C4 ratios, indicating classical pathway activation. The level of complement deficiency appears to correlate with either prolongation of the prothrombin time or depression of serum albumin concentration. These results indicate that patients with hepatic disease have severe complement depletion that is probably multifactorial in origin. This impairment in complement function will contribute to the impaired antibacterial host defense of the patient with chronic hepatic disease.

Explore related subjects

Complement System ProteinsFemaleHumansLiverLiver DiseasesMaleProthrombin TimeReference ValuesRetrospective StudiesComparative StudyJournal ArticleResearch Support, U.S. Gov't, Non-P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R T Ellison, C R Horsburgh, J Curd. 1990. Complement levels in patients with hepatic dysfunction.. https://doi.org/10.1007/bf01536768

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Flow cytometry cross-match: a method for predicting graft rejection.

Long-term graft survival is mainly influenced by early graft rejection and posttransplant graft function. The ability of both complement-dependent cytotoxicity cross-match (CDC) and flow cytometry cross-match (FCXM) to predict acute rejection episodes has been evaluated by cross-matching 40 patients who received cadaveric kidney transplants, before (current serum) and after transplantation (on days 1, 7, 14, 21, 28, 60, and 90). Of the 40 patients, all of whom had a negative CDC before transplant, seven patients had a positive FCXM before transplant: five of them (5/7=71.4%) experienced severe rejection within 2 months after transplantation. In patients with a negative FCXM before transplant, the incidence of acute rejection was lower (25.8%). Pre-transplant FCXM recipients who had a positive FCXM after transplant, experienced more frequent rejection (38.5%) than those pre-transplant FCXM recipients who never had a positive FCXM (15.8%). With respect to the incidence of acute graft rejection, no difference was found between patients who had a positive CDC after transplant and those who had a negative CDC after transplant. Patients who had a positive FCXM before transplant had significantly higher creatinine levels within the first month after transplant. Immediate onset of function and accelerated lowering of the creatinine level were found to be more frequent in patients who had a negative FCXM before transplant. As early graft rejection is the largest contributing factor for the development of chronic rejection and, therefore, of graft loss, we regard FCXM as a sensitive method for predicting long-term prognosis and graft survival, due to its competence in predicting both restricted graft function and early acute rejection, in particular.

Complement System Proteins↗
PubMed1997

The role of immunoglobulin G and fibrinogen in platelet aggregation by Streptococcus sanguis.

Previous work has shown that the type strain of Streptococcus sanguis, NCTC 7863, induces aggregation of normal platelets by a complement-dependent mechanism. We investigated the roles of IgG and fibrinogen in the aggregation process. Plasma depleted of IgG by passage through protein A-sepharose failed to support platelet aggregation, as did plasma absorbed at 0 degrees C with whole bacteria. However, absorption of plasma with a non-aggregating strain of S. sanguis, SK96, did not remove aggregating activity for NCTC 7863. Supplementing 0 degrees C-absorbed plasma with purified IgG restored the aggregation supporting activity. A monoclonal antibody to the Fc gammaRII receptor inhibited platelet aggregation by the bacteria, indicating a requirement for bacteria-IgG complexes interacting with the Fc receptor in platelet aggregation. There was a lag time to the onset of platelet aggregation of 7-19 min depending upon the platelet donor, but the length of this lag did not correlate with either total IgG concentration recognizing NCTC 7863 in subjects' plasma, or the concentration any of the four IgG subclasses or with IgG avidity levels. Fibrinogen was shown to bind rapidly to the bacterial cell surface. Monoclonal antibody to GPIIb/IIIa, RGDS peptide, and a specific antagonist for the platelet fibrinogen receptor, GPIIb/IIIa, FK633, inhibited platelet aggregation by NCTC 7863, indicating that platelet aggregation is fibrinogen dependent. These data suggest that platelet aggregation by some strains of S. sanguis requires multiple stimuli/agonists, including IgG-Fc receptor interaction, complement and fibrinogen.

Complement System Proteins↗